Redefining Precision Oncology in India

India is currently witnessing a significant demographic shift toward an older population. Consequently, the prevalence of cancer is rising, yet many cases remain underreported due to limited data systems. To address this, clinicians are increasingly focusing on precision oncology in India. This approach moves beyond standardized Western protocols toward adaptive, tailored strategies. Experts recently convened to discuss how breakthroughs in diagnostics can transition into real-world patient impact.

Improving Early Detection and MCED Tests

Early detection remains the most effective tool for reducing cancer mortality. Dr. Sewanti Limaye highlighted the potential of Multi-Cancer Early Detection (MCED) tests. These liquid biopsies can detect multiple cancer types from a single blood sample. However, current sensitivity levels vary significantly by stage. While these tests achieve approximately 90% sensitivity for stage-3 tumors, they often struggle with earlier stages. Specifically, sensitivity for stage-1 and stage-2 cancers must improve to meaningfully change clinical outcomes in Indian settings.

Leveraging AI for Resource-Limited Settings

Artificial intelligence is becoming a critical assistant in the oncology workflow. AI-driven advancements can bridge severe resource constraints by identifying high-risk patients more efficiently. Moreover, recent Indian government guidelines now categorize AI-based diagnostic software alongside medical devices. This regulatory clarity supports the growth of local startups. These firms are developing tools like \"OncoMark\" to predict tumor behavior. By integrating AI, clinicians can provide more personalized care despite a shortage of specialized infrastructure.

Precision Oncology in India: Addressing Costs and Patents

High therapy costs and patent restrictions frequently block access to newer modalities. Dr. Sameer Bakhshi emphasized that the industry must prioritize original, homegrown solutions over refurbishing Western drugs. Many medications currently used in India are expensive imports. Scaling up clinical trials within the private sector is essential to reduce these costs. Additionally, identifying novel targets and dosage strengths specifically for Indian patients can expand access significantly.

Adapting Guidelines to Local Pharmacogenomics

Relying solely on FDA or Western guidelines can lead to suboptimal results. For example, Indian patients often report higher rates of toxicity because guidelines are based on Western body surface areas. Furthermore, distinct genetic profiles, such as specific EGFR mutations, necessitate region-specific strategies. Dr. Jyoti Bajpai noted that lower doses are often more appropriate for Indian pharmacogenomics. Establishing indigenous protocols is therefore vital for ensuring safer and more effective treatment outcomes.

Frequently Asked Questions

Q1: Why is the sensitivity of MCED tests a concern for early diagnosis?

While MCED tests can detect multiple cancers, their sensitivity is currently much higher for advanced stages. For effective early intervention, innovators must improve precision for stage 1 and stage 2 cancers to detect tumors before they progress.

Q2: How does Indian pharmacogenomics affect cancer drug dosing?

Indian patients often have different genetic markers and smaller body surface areas compared to Western populations. Consequently, Western-recommended dosages may cause higher toxicity or yield different efficacy levels in the Indian context.

Q3: What role does AI play in improving Indian cancer care?

AI helps bridge resource gaps by automating diagnostic tasks and identifying high-risk individuals. It also assists oncologists in navigating complex genomic data to select the most effective personalized therapies for diverse patient populations.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. New Approaches in Cancer Care Promise Transformation, but Building ConsensusRemains Key - ETHealthworld


2. AI fuels new era of cancer detection - BioSpectrum India (2026)


3. Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options - PMC (2025)